Macitentan, a dual endothelin receptor antagonist, in combination with temozolomide leads to glioblastoma regression and long-term survival in mice

Clinical Cancer Research

Volumn 21, Issue 20, 2015, Pages 4630-4641

  Kim, Sun Jin ^a   Lee, Ho Jeong ^a   Kim, Mark Seungwook ^a   Choi, Hyun Jin ^a   He, Junqin ^a   Wu, Qiuyu ^a   Aldape, Kenneth ^a   Weinberg, Jeffrey S ^a   Yung, W K Alfred ^a   Conrad, Charles A ^a   Langley, Robert R ^a   Lehembre, François ^b   Regenass, Urs ^b   Fidler, Isaiah J ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b ACTELION PHARMACEUTICALS LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; GLUTATHIONE TRANSFERASE A5; MACITENTAN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN BCL X; PROTEIN KINASE B; TEMOZOLOMIDE; TRANSCRIPTION FACTOR TWIST; DACARBAZINE; ENDOTHELIN RECEPTOR ANTAGONIST; PYRIMIDINE DERIVATIVE; SULFONAMIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; ASTROCYTE; BRAIN CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CELL DIVISION; CELL PROTECTION; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; DRUG SENSITIVITY; DRUG TOLERABILITY; ENDOTHELIUM CELL; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN CELL; LONG TERM SURVIVAL; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR VOLUME; 3T3 CELL LINE; ANALOGS AND DERIVATIVES; ANIMAL; CELL LINE; DRUG EFFECTS; GLIOMA; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; CELL DIVISION; CELL LINE; CELL LINE, TUMOR; DACARBAZINE; DOWN-REGULATION; ENDOTHELIAL CELLS; ENDOTHELIN RECEPTOR ANTAGONISTS; FEMALE; GLIOBLASTOMA; GLIOMA; HUMANS; MICE; MICE, NUDE; NIH 3T3 CELLS; PYRIMIDINES; SULFONAMIDES;

EID: 84945588133     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-3195     Document Type: Article

References (56)

1. Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med 2008;359: 492-507.
2. Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: a clinical review. JAMA 2013;310:2683-710.
3. Hochberg FH, Pruitt A. Assumptions in the radiotherapy of glioblastoma. Neurology 1980;30:907-11.
4. 6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol 2008;26:4189-99.
5. Bonavia R, Inda MM, Cavenee WK, Furnari FB. Heterogeneity maintenance in glioblastoma: a social network. Cancer Res 2011;71:4055-60.
6. Johnson BE, Mazor T, Hong C, Barnes M, Aihara K, McLean CY, et al. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science 2014;343:189-93.
7. Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 2006;9:157-73.
8. Snuderl M, Fazlollahi L, Le LP, Nitta M, Zhelyazkova BH, Davidson CJ, et al. Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell 2011;20:810-7.
9. Eberhard A, Kahlert S, Goede V, Hemmerlein B, Plate KH, Augustin HG. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Res 2000;60:1388-93.
10. Calabrese C, Poppleton H, Kocak M, Hogg TL, Fuller C, Hamner B, et al. A perivascular niche for brain tumor stem cells. Cancer Cell 2007;11:69-82.
11. Bao S, Wu Q, Sathornsumetee S, Hao Y, Li Z, Hjelmeland AB, et al. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res 2006;66:7843-8.
12. Wang R, Chadalavada K, Wilshire J, Kowalik U, Hovinga KE, Geber A, et al. Glioblastoma stem-like cells give rise to tumour endothelium. Nature 2010;468:829-33.
13. Cheng L, Huang Z, Zhou W, Wu Q, Donnola S, Liu JK, et al. Glioblastoma stem cells generate vascular pericytes to support vessel function and tumor growth. Cell 2013;153:139-52.
14. Sonoda Y, Kanamori M, Deen DF, Cheng SY, Berger MS, Pieper RO. Overexpression of vascular endothelial growth factor isoforms drives oxygenation and growth but not progression to glioblastoma multiforme in a human model of gliomagenesis. Cancer Res 2003;63:1962-8.
15. Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT. Angiogenesis in brain tumours. Nat Rev Neurosci 2007;8:610-22.
16. Gilbert MR, Dignam JJ, Armstron TS, Wefel JS, Blumenthal DT, Vogelbaum MA, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 2014;370:699-708.
17. de Groot JF, Fuller G, Kumar AJ, Piao Y, Eterovic K, Ji Y, et al. Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice. Neuro Oncol 2010;12:233-42.
18. Kedzierski RM, Yanagisawa M. Endothelin system: the double-edged sword in health and disease. Annu Rev Pharmacol Toxicol 2001;41:851-76.
19. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988;332:411-5.
20. Stow LR, Jacobs ME, Wingo CS, Cain BD. Endothelin-1 gene regulation. FASEB 2011;25:16-28.
21. Rosano L, Spinella F, Bagnato A. Endothelin 1 in cancer: biological implications and therapeutic opportunities. Nature Rev Cancer 2013;13: 637-51.
22. Rosano L, Di Castro V, Spinella F, Nicotra MR, Natali PG, Bagnato A. ZD4054, a specific antagonist of the endothelin A receptor, inhibits tumor growth and enhances paclitaxel activity in human ovarian carcinoma in vitro and in vivo. Mol Cancer Ther 2007;6:2003-11.
23. Ha NH, Nair VS, Reddy DN, Mudvari P, Ohshiro K, Ghanta KS, et al. Lactoferrin-endothelin-1 axis contributes to the development and invasiveness of triple-negative breast cancer phenotypes. Cancer Res 2011;71: 7259-69.
24. Rosano L, Cianfrocca R, Spinella F, Di Castro V, Nicotra MR, Lucidi A, et al. Acquisition of chemoresistance and EMT phenotype is linked with activation of the endothelin A receptor pathway in ovarian carcinoma cells. Clin Cancer Res 2011;17:2350-60.
25. Salani D, Taraboletti G, Rosano L, Di Castro V, Borsotti P, Giavazzi R, et al. Endothelin-1 induces an angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Am J Pathol 2000;157: 1703-11.
26. Wu MH, Huang CY, Lin JA, Wang SW, Peng CY, Cheng HC, et al. Endothelin-1 promotes vascular endothelial growth factor-dependent angiogenesis in human chondrosarcoma cells. Oncogene 2014;33:1725-35.
27. Egidy G, Eberl LP, Valdenaire O, Irmler M, Majdi R, Diserens AC, et al. The endothelin system in human glioblastoma. Lab Invest 2000;80:1681-9.
28. Liu Y, Ye F, Yamada K, Tso JL, Zhang Y, Nguyen DH, et al. Autocrine endothelin-3/endothelin receptor B signalingmaintains cellular and molecular properties of glioblastoma stem cells. Mol Cancer Res 2011;9:1668-85.
29. Charalambous C, Hofman FM, Chen TC. Functional and phenotypic differences between glioblastoma multiforme-derived and normal human brain endothelial cells. J Neurosurg 2005;102:699-705.
30. Nie XJ, Olsson Y. Endothelin peptides in brain diseases. Rev Neurosci 1996;7:177-86.
31. Nagashima G, Suzuki R, Asai J, Fujimoto T. Immunohistochemical analysis of reactive astrocytes around glioblastoma: an immunohistochemical study of postmortem glioblastoma cases. Clin Neur Neurosur 2002;104:125-31.
32. Fitzgerald DP, Palmieri D, Hua E, Hargrave E, Herring JM, Qian Y, et al. Reactive glia are recruited by highly proliferative brain metastases of breast cancer and promote tumor cell colonization. Clin Exp Metastasis 2008; 25:799-810.
33. Kim SW, Choi HJ, Lee HJ, He J, Wu Q, Langley RR, et al. Role of the endothelin axis in astrocyte- and endothelial cell-mediated chemoprotection of cancer cells. Neuro-Oncol 2014 Jul 9. [Epub ahead of print].
34. Langley RR, Fan D, Guo L, Zhang C, Lin Q, Brantley EC, et al. Generation of an immortalized astrocyte cell line from H-2Kb-tsA58 mice to study the role of astrocytes in brain metastasis. Int J Oncol 2009;35:665-72.
35. Langley RR, Ramirez KM, Tsan RZ, Van Arsdall M, Nilsson MB, Fidler IJ. Tissue-specific microvascular endothelial cell lines from H-2K(b)-tsA58 mice for studies of angogenesis and metastasis. Cancer Res 2003;63: 2971-6.
36. Bigner SH, Bullard DE, Pegram CN, Wikstrand CJ, Bigner DD. Relationship of an in vitro morphologic and growth characteristics of established human glioma-derived cell lines to their tumorigenicity in athymic nude mice. J Neuropathol Exp Neurol 1981;40:390-409.
37. Li H, Alonso-Vanegas M, Colicos MA, Jung SS, Lochmuller H, Sadikot AF, et al. Intracerebral adenovirus-mediated p53 tumor suppressor gene therapy for experimental human glioma. Clin Cancer Res 1999;5:637-42.
38. Kitange GJ, Carlson BL, Schroeder MA, Grogan PT, Lamont JD, Decker PA, et al. Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts. Neuro Oncol 2009;11:281-91.
39. Zhang RD, Price JE, Fujimaki T, Bucana CD, Fidler IJ. Differential permeability of the blood-brain barrier in experimental brain metastases produced by human neoplasms implanted into nude mice. Am J Pathol 1992; 141:1115-24.
40. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 1991;324:1-8.
41. Eng LF, Ghirnikar RS. GFAP and astrogliosis. Brain Pathol 1994;4:229-37.
42. Borovski T, Beke P, van Tellingen O, Rodermond HM, Verhoeff JJ, Lascano V, et al. Therapy-resistant tumor microvascular endothelial cells contribute to treatment failure in glioblastoma multiforme. Oncogene 2013;32: 1539-48.
43. Wick W, Weller M, van den Bent M, Sanson M, Weiler M, von Deimling A, et al. MGMT testing-the challenges for biomarker-based glioma treatment. Nat Rev Neurol 2014;10:372-85.
44. Borovski T, Verhoeff JJ, ten Cate R, Cameron K, de Vries NA, van Tellingen O, et al. Tumor microvasculature supports proliferation and expansion of glioma-propagating cells. Int J Cancer 2009;125:1222-30.
45. Kim SJ, Kim JS, Park ES, Lee JS, Lin Q, Langley RR, et al. Astrocytes upregulate survival genes in tumor cells and induce protection from chemotherapy. Neoplasia 2011;13:286-98.
46. Schichiri M, Kato H, Marumo F, Hirata Y. Endothelin-1 as an autocrine/paracrine apoptosis survival factor for endothelial cells. Hypertension 1997;30:1198-1203.
47. Cifarelli V, Lee S, Kim DH, Zhang T, Kamagate A, Slusher S, et al. FOXO1 mediates the autocrine effect of endothelin-1 on endothelial cell survival. Mol Endocrinol 2012;26:213-24.
48. Phuphanich S, Carson KA, Grossman SA, Lesser G, Olson J, Mikkelsen T, et al. Phase I safety study of escalating doses of atrasentan in adults with recurrent malignant glioma. Neuro-Oncol 2008;10:617-23.
49. Fizazi KS, Higano CS, Nelson JB, Gleave M, Miller K, Morris T, et al. Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer. J Clin Oncol 2013;31:1740-7.
50. Kefford RF, Clingan PR, Brady B, Ballmer A, Morganti A, Hersey P. A randomized, double-blind, placebo-controlled study of high-dose bosentan in patients with stage IV metastatic melanoma receiving first-line dacarbazine chemotherapy. Mol Cancer 2010;9:69.
51. Iglarz M, Binkert C, Morrison K, Fischli W, Gatfield J, Treiber A, et al. Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist. J Pharm Exp Ther 2008;327:736-45.
52. Gatfield J, Grandjean CM, Sasse T, Clozel M, Nayler O. Slow receptor dissociation kinetics differentiate macitentan from other endothelin receptor antagonists in pulmonary arterial smooth muscle cells. PLoS ONE 2012;7:1-11.
53. Sidharta PN, van Giersbergen PL, Halabi A, Dingemanse J. Macitentan: entry-into-humans study with a new endothelin receptor antagonist. Eur J Clin Pharm 2011;67:977-84.
54. Sun S, Wong TS, Zhang XQ, Pu JK, Lee NP, Day PJ, et al. Protein alterations associated with temozolomide resistance in subclones of human glioblastoma cell lines. J Neuro Oncol 2012;107:89-100.
55. Gilbertson RJ, Rich JN. Making a tumor's bed: glioblastoma stem cells and the vascular niche. Nat Rev Cancer 2007;7:733-36.
56. Liu TJ, LaFortune T, Honda T, Ohmori O, Hatakeyama S, Meyer T, et al. Inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor kinase suppresses glioma proliferation in vitro and in vivo. Mol Cancer Ther 2007;6:1357-67.